Serum profile in preeclampsia and intra-uterine growth restriction revealed by iTRAQ technology

Journal of Proteomics

Volumn 73, Issue 5, 2010, Pages 1004-1017

  Auer, Jana ^a,b,c   Camoin, Luc ^b,c   Guillonneau, François ^b,c   Rigourd, Virginie ^a,b,c,d   Chelbi, Sonia T ^a,b,c   Leduc, Marjorie ^b,c   Laparre, Jérôme ^b,c   Mignot, Thérèse Marie ^a,b,c   Vaiman, Daniel ^a,b,c  

^a INSERM   (France)

^b INSTITUT COCHIN   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Institut de Puericulture   (France)

Author keywords

Biomarkers; iTRAQ; IUGR; Preeclampsia; Serum

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CHYMOTRYPSIN INHIBITOR; HAPTOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PLASMA PROTEIN; RAUWOLFIA ALKALOID; SERPINA 3; TRANSFERRIN; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CHEMISTRY; BLOOD COMPONENT; CHEMICAL LABELING; CLADISTICS; CONTROLLED STUDY; FEMALE; FETOPLACENTAL UNIT; HUMAN; INTRAUTERINE GROWTH RETARDATION; ION EXCHANGE CHROMATOGRAPHY; ISOBARIC TAGS FOR RELATIVE AND ABSOLUTE QUANTIFICATION; MATERNAL PLASMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEDICAL TECHNOLOGY; PLACENTA DISORDER; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANT WOMAN; PRENATAL GROWTH; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN MODIFICATION; QUANTITATIVE ANALYSIS; REVERSED PHASE LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY;

BIOLOGICAL MARKERS; BLOOD PROTEINS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; FETAL GROWTH RETARDATION; HUMANS; PRE-ECLAMPSIA; PREGNANCY; SERPINS;

EID: 77549084453     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2009.12.014     Document Type: Article

References (35)

1. Urban G., Vergani P., Tironi R., Ceruti P., Vertemati E., Sala F., et al. Antithrombotic prophylaxis in multiparous women with preeclampsia or intrauterine growth retardation in an antecedent pregnancy. Int J Fertil Womens Med 52 2-3 (2007) 59-67
2. Riyazi N., Leeda M., de Vries J.I., Huijgens P.C., van Geijn H.P., and Dekker G.A. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol 80 1 (1998) 49-54
3. Sergio F., Maria Clara D., Gabriella F., Giorgia S., Sara De C., Giancarlo P., et al. Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus low-dose aspirin versus low-dose aspirin alone. Hypertens Pregnancy 25 2 (2006) 115-127
4. Barton J.R., and Sibai B.M. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol 112 2 Pt 1 (2008) 359-372
5. Buhimschi I.A., Zhao G., Funai E.F., Harris N., Sasson I.E., Bernstein I.M., et al. Proteomic profiling of urine identifies specific fragments of SERPINA1 and albumin as biomarkers of preeclampsia. Am J Obstet Gynecol 199 5 (2008) 551.e1-551.e16
6. Venkatesha S., Toporsian M., Lam C., Hanai J., Mammoto T., Kim Y.M., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12 6 (2006) 642-649
7. Feinberg B.B. Preeclampsia: the death of Goliath. Am J Reprod Immunol 55 2 (2006) 84-98
8. Fu Q., Garnham C.P., Elliott S.T., Bovenkamp D.E., and Van Eyk J.E. A robust, streamlined, and reproducible method for proteomic analysis of serum by delipidation, albumin and IgG depletion, and two-dimensional gel electrophoresis. Proteomics 5 10 (2005) 2656-2664
9. Eisen M.B., Spellman P.T., Brown P.O., and Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95 25 (1998) 14863-14868
10. Saldanha A.J. Java Treeview-extensible visualization of microarray data. Bioinformatics 20 17 (2004) 3246-3248
11. Dennis Jr. G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4 5 (2003) P3
12. Buffat C., Mondon F., Rigourd V., Boubred F., Bessieres B., Fayol L., et al. A hierarchical analysis of transcriptome alterations in intrauterine growth restriction (IUGR) reveals common pathophysiological pathways in mammals. J Pathol 213 3 (2007) 337-346
13. Buffat C., Boubred F., Mondon F., Chelbi S.T., Feuerstein J.M., Lelievre-Pegorier M., et al. Kidney gene expression analysis in a rat model of intrauterine growth restriction reveals massive alterations of coagulation genes. Endocrinology 148 11 (2007) 5549-5557
14. Borghese B., Mondon F., Noel J.C., Fayt I., Mignot T.M., Vaiman D., et al. Gene expression profile for ectopic versus eutopic endometrium provides new insights into endometriosis oncogenic potential. Mol Endocrinol 22 11 (2008) 2557-2562
15. Kovarik A., Hlubinova K., Vrbenska A., and Prachar J. An improved colloidal silver staining method of protein blots on nitrocellulose membranes. Folia Biol (Praha) 33 4 (1987) 253-257
16. Baumann H., and Gauldie J. The acute phase response. Immunol Today 15 2 (1994) 74-80
17. Kushner I. Regulation of the acute phase response by cytokines. Perspect Biol Med 36 4 (1993) 611-622
18. Wigmore S.J., Fearon K.C., Maingay J.P., Lai P.B., and Ross J.A. Interleukin-8 can mediate acute-phase protein production by isolated human hepatocytes. Am J Physiol 273 4 Pt 1 (1997) E720-E726
19. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340 6 (1999) 448-454
20. Redman C.W., and Sargent I.L. Preeclampsia and the systemic inflammatory response. Semin Nephrol 24 6 (2004) 565-570
21. Chelbi S.T., Mondon F., Jammes H., Buffat C., Mignot T.M., Tost J., et al. Expressional and epigenetic alterations of placental serine protease inhibitors: SERPINA3 is a potential marker of preeclampsia. Hypertension 49 1 (2007) 76-83
22. Blumenstein M., McMaster M.T., Black M.A., Wu S., Prakash R., Cooney J., et al. A proteomic approach identifies early pregnancy biomarkers for preeclampsia: novel linkages between a predisposition to preeclampsia and cardiovascular disease. Proteomics 9 11 (2009) 2929-2945
23. Ustun Y., Engin-Ustun Y., and Kamaci M. Association of fibrinogen and C-reactive protein with severity of preeclampsia. Eur J Obstet Gynecol Reprod Biol 121 2 (2005) 154-158
24. Wang Y., Walli A.K., Schulze A., Blessing F., Fraunberger P., Thaler C., et al. Heparin-mediated extracorporeal low density lipoprotein precipitation as a possible therapeutic approach in preeclampsia. Transfus Apher Sci 35 2 (2006) 103-110
25. Deveci K., Sogut E., Evliyaoglu O., and Duras N. Pregnancy-associated plasma protein-A and C-reactive protein levels in pre-eclamptic and normotensive pregnant women at third trimester. J Obstet Gynaecol Res 35 1 (2009) 94-98
26. Garcia R.G., Celedon J., Sierra-Laguado J., Alarcon M.A., Luengas C., Silva F., et al. Raised C-reactive protein and impaired flow-mediated vasodilation precede the development of preeclampsia. Am J Hypertens 20 1 (2007) 98-103
27. Paternoster D.M., Fantinato S., Stella A., Nanhorngue K.N., Milani M., Plebani M., et al. C-reactive protein in hypertensive disorders in pregnancy. Clin Appl Thromb Hemost 12 3 (2006) 330-337
28. Chelbi S.T., and Vaiman D. Genetic and epigenetic factors contribute to the onset of preeclampsia. Mol Cell Endocrinol 282 1-2 (2008) 120-129
29. Rigourd V., Chauvet C., Chelbi S.T., Rebourcet R., Mondon F., Letourneur F., Mignot T.M., Barbaux S., and Vaiman D. STOX1 overexpression in choriocarcinoma cells mimics transcriptional alterations observed in preeclamptic placentas. PLoS ONE 3 12 (2008) e3905
30. Rigourd V., Chelbi S., Chauvet C., Rebourcet R., Barbaux S., Bessieres B., et al. Re-evaluation of the role of STOX1 transcription factor in placental development and preeclampsia. J Reprod Immunol 82 2 (2009) 174-181
31. Hiby S.E., Walker J.J., O'Shaughnessy K.M., Redman C.W., Carrington M., Trowsdale J., et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med. 200 8 (2004) 957-965
32. Leeflang M.M., Cnossen J.S., van der Post J.A., Mol B.W., Khan K.S., and ter Riet G. Accuracy of fibronectin tests for the prediction of pre-eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol 133 1 (2007) 12-19
33. Biro E., Lok C.A., Hack C.E., van der Post J.A., Schaap M.C., Sturk A., et al. Cell-derived microparticles and complement activation in preeclampsia versus normal pregnancy. Placenta 28 8-9 (2007) 928-935
34. Spencer K., Yu C.K., Rembouskos G., Bindra R., and Nicolaides K.H. First trimester sex hormone-binding globulin and subsequent development of preeclampsia or other adverse pregnancy outcomes. Hypertens Pregnancy 24 3 (2005) 303-311
35. Oishi K. Plasminogen activator inhibitor-1 and the circadian clock in metabolic disorders. Clin Exp Hypertens 31 3 (2009) 208-219